A major 2026 regulatory milestone is the widespread approval of "interchangeable" designations for ustekinumab biosimilars. In 2026, drugs like Wezlana have set a new standard, allowing pharmacists to automatically substitute the lower-cost biosimilar for the brand-name version without needing a new prescription from a doctor. This 2026 movement is currently identified as the single biggest...
จองคิวบริการ
NR tours
Youplay
NR shop
NR jobs
facebook th
thai 
English
French
Spanish
Portuguese
Italiano
Romaian
Portuguese (Brazil)
china